a blood Review to replace the biopsy

 Tuesday November 5, 2019.

At the ESMO 2019 Congress held in late September in Spain, researchers presented a new blood Review for patients with lung cancer. It would replace the biopsy.

 

A blood Review instead of a biopsy

The fight against cancer continues and this is another step that has just been taken with a new blood Review. Intended for patients with a certain type of lung cancer, it would avoid the biopsy. No more taking a tumor sample to analyze it, a simple blood Review would suffice.

This new blood Review was presented at the ESMO Congress 2019 which took place in late September 2019 in Barcelona, ​​Spain. Shirish Gadgeel of the University of Michigan in the United States and his team gave details of their discovery. They explained how Review identifies complex DNA mutations in cells of non-small cell lung cancer patients (NSCLC, the most common form) that are suitable for the latest targeted drugs. The Review could help doctors choose the best treatment for patients.

 

High cost but expected to fall

" One of the biggest recent changes in the treatment of NSCLC has been our ability to identify targeted genetic mutations that cause disease progression, but it is very difficult to obtain an appropriate tumor sample for analysis Explained Shirish Gadgeel. This new blood Review would replace the biopsy and get the same results.

An encouraging discovery but which is still very expensive. However, according to Professor Alberto Bardelli, of the Department of Oncology at the University of Turin, Italy, the more this Review is used, the more its cost will drop.

 Perrine Deurot-Bien

Read also Breast cancer: men also affected